188 related articles for article (PubMed ID: 24061041)
41. Temsirolimus in the treatment of advanced renal cell carcinoma.
Gore ME
Ann Oncol; 2007 Jul; 18 Suppl 9():ix87-8. PubMed ID: 17631601
[No Abstract] [Full Text] [Related]
42. Emerging targeted therapies in metastatic renal cell carcinoma.
Matrana MR; Atkinson B; Jonasch E; Tannir NM
Curr Clin Pharmacol; 2011 Aug; 6(3):189-98. PubMed ID: 21827388
[TBL] [Abstract][Full Text] [Related]
43. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
44. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
45. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
46. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.
Jones J; Otu HH; Grall F; Spentzos D; Can H; Aivado M; Belldegrun AS; Pantuck AJ; Libermann TA
J Urol; 2008 Feb; 179(2):730-6. PubMed ID: 18082202
[TBL] [Abstract][Full Text] [Related]
47. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
48. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Ficarra V; Novara G
Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580
[No Abstract] [Full Text] [Related]
49. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Van Poppel H
Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572
[No Abstract] [Full Text] [Related]
50. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.
Pal SK; Vogelzang NJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):146-55. PubMed ID: 23598982
[TBL] [Abstract][Full Text] [Related]
51. Optimizing recent advances in metastatic renal cell carcinoma.
Courtney KD; Choueiri TK
Curr Oncol Rep; 2009 May; 11(3):218-26. PubMed ID: 19336014
[TBL] [Abstract][Full Text] [Related]
52. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N; Choueiri TK; Lee JL; Bjarnason GA; Knox JJ; MacKenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Tan MH; Bamias A; Kollmannsberger CK; North SA; Rini BI; Heng DY
Eur Urol; 2014 Jun; 65(6):1086-92. PubMed ID: 23916693
[TBL] [Abstract][Full Text] [Related]
53. Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.
Rodriguez AR; Fishman MN
Expert Opin Pharmacother; 2007 Dec; 8(17):2979-90. PubMed ID: 18001257
[TBL] [Abstract][Full Text] [Related]
54. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
55. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
56. [Biomarker for molecular targeting therapy against renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
[No Abstract] [Full Text] [Related]
57. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
58. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
59. Metastatic renal cancer: better never than late.
Galsky MD
Eur Urol; 2014 Jun; 65(6):1093-4. PubMed ID: 23954087
[No Abstract] [Full Text] [Related]
60. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]